Filter by
Filter by
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
A review article by the Upenn group summarized the preclinical and clinical evidence for the FLASH effect and discussed the potential clinical significance for...
Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma
This study included148 chordoma and chondrosarcoma patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1cm3...
Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy.
This study reported outcomes of 48 patients with skull base chondrosarcoma who underwent particle therapy (67% PT, 33% CIRT). With a median follow-up of 38...
Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomas.
Sixty-seven patients with unresected spinal chordomas treated with PBT were evaluated. With a median follow-up of 56.2 months, 5- and 8-year OS were 83.5 % and...
Proton or Carbon Ion Therapy for Skull Base Chordoma: Rationale and First Analysis of a Mono-Institutional Experience.
This study reported clinical outcomes of 44 patients treated with proton (89%) or carbon ion therapy (11%). At a median follow-up of 34.3 months, 2-, and 3-year...
The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma.
This study reported the outcomes of 20 patients with primary (N=18), metastatic (N=3), or recurrent (N=2) inoperable pelvic (70%) or craniofacial (30%)...
Proton Therapy for Primary Bone Malignancy of the Pelvic and Lumbar Region - Data From the Prospective Registries ProReg and KiProReg.
Eighty-one patients with primary bone malignancy, including Ewing’s sarcoma (58%), chondrosarcoma (7.4%), chordoma (24.7%), osteosarcoma (7.4%), and...